pembrolizumab
merck
['sclc', 'lung', 'pembro', 'nsclc']
biagio ricciuti, md, spoke about patients with non small cell lung cancer with a very high pd-l1 tumor proportion score of 90% or more who were treated with first-line pembrolizumab monotherapy. #nsclc #asco22 | 
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.